Clinical Trials Logo

Optic Nerve Diseases clinical trials

View clinical trials related to Optic Nerve Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06031350 Completed - Clinical trials for Non-arteritic Ischemic Optic Neuropathy

Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study

Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

This series aims at studying the peripapillary and macular vascular changes in subjects with unilateral anterior ischemic optic neuropathy via Optical Coherence Tomography Angiography (OCTA).

NCT ID: NCT05895851 Completed - Clinical trials for Optic Radiation Neuropathy Following Radiotherapy Procedure

Optical Coherence Tomography Angiography Characteristics of Radiation Optic Neuropathy

Start date: June 1, 2018
Phase:
Study type: Observational

Aim: To develop a suitable radiation optic neuropathy (RON) diagnostic model based on optical coherence tomography angiography (OCTA) and to reveal the correlation between endocrine and OCTA indexes in nasopharyngeal carcinoma (NPC) patients with radiation encephalopathy (RE). Methods: This retrospective cross-sectional study included 80 male NPC patients with RE following radiotherapy (40 non-RON and 40RON). Endocrine and OCTA indexes were collected. The macular and peripapillary vessel density (VD) were automatically analyzed using AngioVue 2.0 of the RTVue XR Avanti device. The OCTA indexes were included in the multivariable binary logistic regression model between non-RON and RON. For all RE patients, a multiple linear regression was performed between each of the OCTA indexes and the endocrine indexes.

NCT ID: NCT05853003 Completed - Optic Neuropathy Clinical Trials

Neuromuscular Ultrasonography Assessment of Optic Nerve in Systemic Lupus Eryhematosus

Start date: January 1, 2022
Phase:
Study type: Observational

assessing the role of neuromuscular ultrasound in optic nerve involvement in systemic lupus patients.

NCT ID: NCT05555784 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy (LHON)

Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection

Start date: August 4, 2022
Phase:
Study type: Observational

Leber's hereditary optic neuropathy (LHON) is a rare mitochondrial genetic disorder characterized by optic nerve atrophy due to the degeneration of retinal ganglion cells, which leads to acute visual loss. Males are more likely to develop optic neuropathy than women. They experience blurring or clouding of vision in one eye. The fellow eye develops similar symptoms sequentially with a delay of weeks. This sudden vision loss has devastating consequences on the life course of young men, with the impact of LHON on their quality of life and loss of independence. Yet, data describing the impacts of LHON on the life-course of patients is lacking, with very little data available in the literature. This study aims to understand the life of patients living with LHON disease through the analysis of the impact of LHON on the quality of life and loss of independence of patients living in France and to accurately describe the consequences of the disease on their social, familial and professional life.

NCT ID: NCT04909398 Completed - Clinical trials for Retinitis Pigmentosa

Pupil Dynamics and Color Vision for the Detection of Eye Diseases

PupDyn
Start date: March 22, 2018
Phase: N/A
Study type: Interventional

The development of new oculometry techniques allows fine and dynamic measurements of pupillary diameter and use in routine clinical practice. The preliminary results obtained with innovative devices on healthy sjuets make it possible to envisage a clinical study on a population of patients suffering from retinal pathologies. This is a "proof of concept" study, which, if the expected results are confirmed, will make it possible to consider a study on a larger population, as well as the industrial development of a commercial device.

NCT ID: NCT04891211 Completed - Clinical trials for Vitamin D Deficiency

Retinal Changes in Vitamin D Deficiency

VDD
Start date: February 12, 2021
Phase: N/A
Study type: Interventional

Retinal tissue parameters of pediatric patients with vitamin D deficiency will be evaluated in this prospective case-control study. The patients will be divided into 2 groups according to the vitamin D level. Retinal vessel diameters, retinal nerve fiber evaluation, choroidal thickness will be evaluated. Choroidal thinning decrease in retinal artery diameter and increase in retinal vein diameter will be detected in the vitamin D deficiency group.

NCT ID: NCT04877067 Completed - Clinical trials for Magnetic Field Exposure

Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation

Magnovision
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The axons of the retinal ganglion cells combine to form the optic nerve. The optic nerve transmits electrical signals to the visual cortex by various synapses. Optic nerve axons are more sensitive to toxins than retina because they are outside the blood retinal barrier. Methanol, various solvents and heavy metals, carbon dioxide, antiarrhythmic, antiepileptic, antibiotics and some vasoactive drugs can cause toxic optic neuropathy. There is a different pathophysiology for each toxin. Methanol is easily accessible alcohol in all types of disinfectants. Methanol is converted into formaldehyde and formic acid while metabolized in the liver. Formaldehyde disrupts ATP synthesis by blocking mitochondrial function and oxidative phosphorylation. Formic acid causes demyelination as a result of metabolic acidosis. Neuroinflammation occurs when denatured proteins block axoplasmic flow. All these processes can lead to apoptosis and permanent vision loss. Sildenafil is a vasoactive drug used in erectile dysfunction. Sildenafil decreases optic nerve head blood flow. Neuroinflammation develops secondary to the cessation of axoplasmic flow after hypoxia. If hypoxia and neuroinflammatiom persists, apoptosis and permanent vision loss develop. Amiodarone is an ion channel blocker used in the treatment of cardiac arrhythmias. Long-term use may cause disruption of ion channel balance in the optic nerve. This condition leads to asymmetric neuroinflammation and apoptosis. Wharton's jelly derived mesenchymal stem cells (WJ-MSC) can increase mitochondrial ATP synthesis with paracrine effects and suppress neuroinflammation with immunomodulatory effects. Repetitive electromagnetic stimulation (rEMS) can rearrange ion channel balances and axoplasmic flow. The aim of this prospective phase-3 clinical study is to investigate the effect of WJ-MSC and rEMS combination in the therapy of toxic optic neuropathies. This combination is the first study in the literature for the therapy of toxic optic neuropathies.

NCT ID: NCT04561466 Completed - Safety Issues Clinical Trials

Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

Béfinohl
Start date: March 26, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Study of the efficiency of Béfizal® 200 mg in 14 adult patients with a LHON that occurred for less than 5 years. Patient must have certain specific mutations

NCT ID: NCT04469777 Completed - Optic Neuropathy Clinical Trials

Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Start date: April 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

NCT ID: NCT04125043 Completed - Retinal Disease Clinical Trials

Accuracy of the Red Reflex Test in the Pediatric Population

Start date: March 1, 2020
Phase:
Study type: Observational

This study is designed to investigate the sensitivity and specificity of the Red Reflex Test (RRT), with and without dilation, for early detection of ocular abnormalities in children and newborns. The RRT functions by shining a light from an ophthalmoscope into a participant's eye and noting the presence or absence of a red glow. Despite its use in pediatric clinics for years, this test at times fails to detect significant ocular diseases, especially located in the back of the eye, threatening visual development in this population. Therefore, the investigators aim to quantify the utility of this test as a tool for screening by comparing these findings on RRT with those of retinal photography. The investigators hypothesize that the sensitivity and specificity of the RRT will be sufficient for detecting anterior segment pathology but will be insufficient for detecting posterior segment pathology with or without dilation.